High costs in drug development are due to multiple complex contributors like scientific discovery processes, infrastructure, collaborations, clinical development duration, safety studies, efficacy studies, market research, and clinical trial costs, to name a few . Conducting clinical trials amidst knowing the efficacy and value of drugs, regulatory scrutiny, population, rising costs remains a core challenge for pharma . Starting with a big positive shift away from the dip in approvals between 2015-17 , the data published by FDA (the annual New Drug Approvals Report) suggest that an average of 46 drugs have been approved per year across the past 5 years. Nonetheless, the success rate of molecules to transition from Phase II to III is the least , and hence exemplifies the phase transition that carries the highest risk. Further, studies indicate that there are higher chances of a molecule being launched as a drug when it reaches Phase III.